Metropolis Healthcare Ltd. · NSE:METROPOLIS
Metropolis Healthcare — Q2 FY2025 Earnings Presentation
28 slides from Metropolis Healthcare's earnings presentation, Nov 8, 2024
Slide 1: Stock exchange cover letter - Investor Presentation
Ref: MHL/Sec&Legal/2024-25/63 Date: November 08, 2024 To, BSE Limited National Stock Exchange of India Ltd. Scrip Code: 542650 Scrip Symbol: METROPOLIS Dear Sir/Madam, Sub: Investor Presentation Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we
Slide 2: Metropolis Healthcare Limited Q2FY25 Investor Presentation
METROPOLIS HEALTHCARE LIMITED Q2FY25 INVESTOR PRESENTATION
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Metropolis Healthcare Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Content
Performance Highlights 1 Financial performance indicators Segment, volume and other Operational KPIs 2 performance indicators Content Performance and Company Profit & Loss 3 Income Statement Updates Q2FY25 Metropolis 3.0 Metropolis 3.0 strategy including Strategy 4 network, digital, science and qual
Slide 5: Metropolis – Diagnostics that's trusted by doctors and patients alike
Metropolis – Diagnostics that’s trusted by doctors and patients alike OUR VISION To be a respected healthcare brand trusted by 43+ years of clinicians, patients and stakeholders. 12% CAGR credible Positively impact the lives of patients in their revenue growth experience most anxious times and turn
Slide 6: Q2FY25 Financial Highlights
Q2FY25 Financial Highlights Revenue EBIDTA PAT INR 350 Cr INR 92 Cr INR 47 Cr 13.4% YoY 22.2% YoY 31.0% YoY Q2FY25 EBITDA at 26.2% and PAT at 13.4%, increase of 190 bps and 180 bps YoY respectively Consistent delivery on revenue and Margin growth, as per guidance Margins growing faster than revenue
Slide 7: H1FY25 Financial Highlights
H1FY25 Financial Highlights Revenue EBIDTA PAT INR 663 Cr INR 170 Cr INR 85 Cr 13.2% YoY 21.7% YoY 31.3% YoY H1 EBITDA at 25.6% and PAT at 12.8%, increase of 180 bps YoY in both YoY Revenue in H1FY25 has grown higher than in H1FY24 5
Slide 8: Q2FY25 Key Performance Indicators
Q2FY25 Key Performance Indicators • Consistent growth in patient and test volumes Patient Volume B2C Revenue B2B Revenue • B2C Patient Volume Growth at 12% 3.41 Mn INR 194 Cr INR 127 Cr • Revenue growth excl. the 7% YoY 21%YoY institutional business stood at ~17% 13%YoY i.e. B2C (21%) + B2B (13%). P
Slide 9: Robust revenue on consistent Patient & Test Volume growth
Robust revenue on the back of consistent Patient & Test Volume growth @ 7% & 8% respectively Patient Volume (in Mn) Test Volume (in Mn) Q2FY25 Segment Contribution Revenue Growth 9.7% Routine 15% 7% 9% Routine 16% 20% 7% 8% Semi-Special Semi-Special 6% 6.04 6.45 12.26 13.33 Specialty Specialty 16% 3
Slide 10: Strong B2C revenue growth @ 21% YoY in Q2FY25
Strong B2C revenue growth @ 21% YoY in Q2FY25 o B2C Patient volume grew by 12% & RPP by 8% o Strong Clinician Engagement scientifically reinforcing doctor preference and trust +24% 56% +27% o Franchisee Partner (+400bps) +23% programme launched to motivate, reward and recognize partners o Digital re
Slide 11: B2B revenue growing by 13% YoY in Q2FY25
B2B revenue growing by 13% YoY in Q2FY25 – consistent double -digit growth, second quarter in a row o B2B patient volume grew by 4% & RPP by 8% +21% o Higher B2B Engagement via Partner portal, helpdesk and service differentiation through segmentation 36% +13% +10% o Dedicated approach to improve B2B
Slide 12: TruHealth Revenue grew @ 23% YoY
TruHealth Revenue grew @ 23% YoY o Margin-accretive packages with average realizations exceeding Rs. 2,500. Growth o Increase in TruHealth Contribution in Q2FY24 of 14% to 16% now in Q2FY25. 8% increase in Test Volume and 14% increase in RPT through selling of higher 23% end packages o Driven throug
Slide 13: Speciality Revenue grew @ 16% YoY
Speciality Revenue grew @ 16% YoY o Over 3,000 specialty tests and uniquely designed profiles across Gastroenterology, Specialty Growth Nephrology, Neurology, Oncology, Women & Child Health, Infectious, and Chronic Diseases. o Consistent growth in Specialty Segment - FY24 – 13.8%, Q1FY25 - 14%, Q2FY
Slide 14: Network Expansion - on course to add labs & service centers
Network Expansion - on course to add 90 labs & 2000 service centers by FY25 Laboratory Network Service Network 199 202 4,150 4,216 4,336 Rationalization Period 175 3,675 841 805 816 161 +77 2,731 3,134 754 +1,781 119 124 125 2,555 704 2,336 Labs* 598 498 Centres 575 2,929 3,009 2,914 2,594 2,105 Rur
Slide 15: Diversified Revenue contribution across Geographies
Diversified Revenue contribution across Geographies Revenue Contribution Revenue Growth (MHL Categorisation) Focus 10% By Cities 20% Focus Seeding Seeding 7% 18% Others 62% Others 23% Presence in Revenue Contribution Revenue Growth ~700 towns Network expansion leading to 26% T1 8% By City Tier Tier
Slide 16: Q2 FY25 Consolidated Profit & Loss Statement
Q2 FY25 Consolidated Profit & Loss Statement Profit & Loss Statement (Rs. Crs.) Q2FY25 Q2FY24 Y-o-Y H1FY25 H1FY24 Y-o-Y Revenue from Operations 349.8 308.5 13.4% 663.1 585.6 13.2% Costs 258.3 233.7 10.6% 493.5 446.2 10.6% Reported EBIDTA 91.5 74.9 22.2% 169.7 139.4 21.7% Reported EBIDTA (%) 26.2% 24
Slide 17: Balance Sheet Overview
Balance Sheet Overview Assets (Rs. Crs.) H1FY25 Mar-24 Mar-23 Equity & Liabilities (Rs. Crs.) H1FY25 Mar-24 Mar-23 Equity 1,187.4 1,099.3 990.8 Non-current assets 1,240.9 1,239.2 1,198.8 Equity Share capital 10.2 10.2 10.2 Property, Plant and Equipment 164.4 155.9 137.2 Other equity 1,173.7 1,085.9
Slide 18: Balance Sheet Ratios
Balance Sheet Ratios ROI- Invested CCE Actual vs Target Cash and Cash Equivalents DSO 8.5% INR Cr 185 30 30 7.4% 7.5% 124 Mar-24 Jun-24 Sep-24 Actual 7.4% 7.5% 8.5% MarCategory 24 Sep Mar 24 Sep1 24 1 24 Category o The stability in DSO indicates consistent collection efficiency, with no significant
Slide 19: Metropolis 3.0
Metropolis 3.0 METROP®OLIS
Slide 20: Key Pillars of Metropolis 3.0 Strategy
Key Pillars of Metropolis 3.0 Strategy – poised to grow further 1 Strengthening the Core Expand market share in core and newer geographies with a focus on specialized and wellness testing, while creating a differentiated brand and empowering with AI and digitization Expand to Adjacencies while Forgi
Slide 21: Driving business growth through Digital Transformation
Driving business growth through Digital Transformation Metropolis is a unique Healthcare Company equipped with SalesForce CDP, Marketing Cloud, Service Cloud, Sales Cloud, Community Cloud Accurate Efficient Efficient Patient 360-Degree Opportunity Case Relationship Reporting & Cross Channel Enhanced
Slide 22: Scientifically driven with strong focus on quality, research and academics
Scientifically driven with strong focus on quality, research and academics Scientific Expansion in Test Menu • New test launched across Oncology, Nephrology, Gynecology and 102 New Tests added in FY24 Infectious and Chronic disease segment • Focus on NGS/molecular genomics segment growing driven by
Slide 23: Metropolis ESG Goals
Metropolis ESG’ Goals • Carbon Neutrality by 2043 Emission Goals for a Greener Tomorrow • 45% reduction in emissions intensity by 2030 Well identified ESG Focus Areas and assessments created e as per the materiality matrix based on the GRI, SASB and SDG Frameworks. Our first Business Responsibility
Slide 24: Key ESG Plans 2024-25
Key ESG Plans 2024-25 Emissions & Water & Waste Employee Risk Management Patient Privacy and Energy Management Recruitment, Electronic Health Development and Records Retention • Achieve 5% reduction in • Career 2.0 Campaign to increase • Annual assessments of Risk • 100% training on information • Ac
Slide 25: CSR at Metropolis – creating a positive impact
CSR at Metropolis – creating a positive impact Preventive DSEU* (Delhi Skills MedEngage Too Shy to Ask(TSTA) Entrepreneurial healthcare Project University) • Integrating all UG and PG • TSTA Rural focusing on adolescent • 1000 TB patients to receive programs including reproductive and sexual health,
Slide 26: 'Promoter led – Professionally driven' organisation
‘Promoter led – Professionally driven’ organisation Dr. Sushil Shah Ameera Shah Surendran Chemmenkotil Chairman Emeritus Promoter & Executive Chairperson Chief Executive Officer Dynamic Leadership Team for Next Level of Growth Dr. Nilesh Shah Kannan Alangadan Dr. Kirti Kazi Ishita Medhekar Dr. Punee
Slide 27: Recent Awards and Accolades
Recent Awards and Accolades Ameera Shah - Healthcare Icon/Leader of the Year Award at the ET Healthcare Excellence Sept’24 Awards 2024 Gold Award for Best Content Marketing & Bronze Award for Best Social Media Jul’24 Communication at E4M Health & Wellness Marketing Awards 2024 Gold Award - Diagnosti
Slide 28: For further information, please contact
For further information, please contact: Company : Investor Relations Advisors : http://www.sgapl.net/images/sgapl_logo.jpg Metropolis Healthcare Ltd. Strategic Growth Advisors Pvt. Ltd. CIN – L73100MH2000PLC192798 CIN - U74140MH2010PTC204285 Mr. Kamlesh Kulkarni Mr. Shogun Jain / Mr. Sagar Shroff E
Metropolis Healthcare — Q2 FY2025 Earnings Presentation on 6ix